Dark

Check out our Level2View

ZIOP
ZIOPHARM Oncology Inc.
stock NASDAQ

Inactive

Jan 26, 2022

0.8657USD-0.882%(-0.0077)2,127,546

Pre-market

Dec 31, 1969 7:00:00 PM EST

0.00USD-100.000%(-0.87)0

After-hours

Dec 31, 1969 7:00:00 PM EST

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 26, 2022

11:20AM EST Ziopharm Rebrands As Alaunos Therapeutics Benzinga

08:29AM EST The Daily Biotech Pulse: Gilead's Blood Cancer Studies Placed On Partial Clinical Hold, Immunocore Gets FDA Nod, NRx Touts Positive COVID-19 Data Benzinga

07:22AM EST Ziopharm Oncology Highlights Operational Progress & Rebrands To Alaunos Therapeutics Benzinga

07:00AM EST -- Phase 1/2 TCR-T Library trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications is open for enrollment; continue to expect to dose the first patient in 1H 2022 GlobeNewswire Inc

Nov 18, 2021

12:35PM EST Ziopharm Sponsored Study Titled 'HLA Typing and Tumor Neoantigen Identification for a Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors' Posted To ClinicalTrials.gov; Study Is Recruiting Benzinga

Nov 9, 2021

11:43AM EST Ziopharm Oncology To Present Preclinical Data Supporting TCR-T Library Approach At The Society For Immunotherapy Of Cancer 2021 Annual Meeting Nov. 13 Benzinga

11:36AM EST Raymond James Maintains Market Perform on ZIOPHARM Oncology, Lowers Price Target to $2 Benzinga

11:07AM EST ZIOPHARM Oncology Q3 EPS $(0.11) Beats $(0.13) Estimate Benzinga

08:05AM EST Ziopharm Oncology, Inc. (Ziopharm or the Company) (Nasdaq: ZIOP), today announced the presentation of preclinical data highlighting the potential of neoantigen-specific TCR-T cells for the treatment of solid tumors at the Society for Immunotherapy of Cancer 2021 Annual Meeting. GlobeNewswire Inc

Nov 8, 2021

04:10PM EST Ziopharm Oncology, Inc. (Ziopharm or the Company) (Nasdaq: ZIOP), today announced financial results for the third quarter ended September 30, 2021 and provided a business update. GlobeNewswire Inc

05:06AM EST Earnings Scheduled For November 8, 2021 Benzinga

Nov 1, 2021

04:30PM EDT Ziopharm Oncology to Report Third Quarter Financial Results on GlobeNewswire Inc

Oct 5, 2021

05:02AM EDT Ziopharm Oncology Director Jamie Vieser Reported Purchase of 100,000 Shares @ Avg Price of $1.91 in Form 4 Filing on Monday Benzinga

Sep 27, 2021

04:06PM EDT Ziopharm Oncology Announces Strategic Reduction in Workforce, Extension In Cash Runway Benzinga

04:05PM EDT Ziopharm Oncology Announces Strategic Reduction in Workforce and GlobeNewswire Inc

Sep 7, 2021

06:25AM EDT The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 6.10 A.M. EDT). RTTNews

Sep 1, 2021

04:05PM EDT Ziopharm Oncology, Inc. (Ziopharm or the Company) (Nasdaq: ZIOP), today announced that Kevin S. Boyle, Sr., Chief Executive Officer of Ziopharm, is scheduled to participate in five upcoming virtual investor conferences: GlobeNewswire Inc

Aug 30, 2021

08:58AM EDT Ziopharm Oncology Appoints Kevin Boyle As CEO RTTNews

08:30AM EDT Mr. Boyle brings over 20 years of executive business leadership in CEO, CFO and operational leadership roles GlobeNewswire Inc

Aug 20, 2021

07:45AM EDT The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data Benzinga

Aug 18, 2021

07:38AM EDT The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga

Aug 17, 2021

08:28AM EDT The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business Benzinga

Aug 13, 2021

07:43AM EDT The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO Benzinga

Aug 11, 2021

08:14AM EDT The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering Benzinga

Aug 10, 2021

10:32AM EDT Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2021 Benzinga

05:09AM EDT Raymond James Downgrades ZIOPHARM Oncology to Market Perform, Announces $3 Price Target Benzinga

Aug 9, 2021

05:08PM EDT Ziopharm Reports Cash, Cash Equivalents $76.7M As Of Jun. 30, 2021 Benzinga

04:05PM EDT Accomplished key milestones in groundbreaking TCR-T Library program, including commissioning of Companys manufacturing facility and presentation of favorable preclinical data GlobeNewswire Inc

11:07AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

04:11AM EDT Earnings Scheduled For August 9, 2021 Benzinga

Aug 8, 2021

10:11AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

Jul 26, 2021

04:30PM EDT Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that management will host a conference call and webcast on Monday, August 9, at 4:30 p.m. EDT to provide a corporate update and discuss financial results for the second quarter ended June 30, 2021. GlobeNewswire Inc

Jun 9, 2021

10:13AM EDT Mid-Morning Market Update: Markets Mixed; Campbell Soup Profit Misses Views Benzinga

May 24, 2021

04:05PM EDT Ziopharm Oncology, Inc. (Ziopharm or the Company) (Nasdaq: ZIOP), a clinical-stage cellular therapy company focused on hematologic and solid tumor cancers, today announced that Company management will participate in two upcoming investor conferences: GlobeNewswire Inc

May 19, 2021

04:05PM EDT Highlighted distinctive cellular therapy program, market opportunity and value proposition GlobeNewswire Inc

May 7, 2021

08:43AM EDT Raymond James Maintains Outperform on ZIOPHARM Oncology, Lowers Price Target to $4 Benzinga

May 6, 2021

04:37PM EDT ZIOPHARM Oncology Q1 EPS $(0.10), Inline Benzinga

04:17AM EDT Earnings Scheduled For May 6, 2021 Benzinga

May 4, 2021

08:00AM EDT Ziopharm Oncology, Inc. (Ziopharm or the Company) (Nasdaq: ZIOP), announced today that Laurence J.N. Cooper, PhD, MD, Scientific Advisor to the Company, will present and participate in an upcoming panel discussion at the University of Pennsylvanias upcoming Cellicon Valley symposium, May 6-7, 2021. GlobeNewswire Inc

Apr 29, 2021

09:00AM EDT Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced it will report first quarter 2021 financial results on Thursday, May 6, 2021 after the financial markets close, and host its annual shareholder meeting on May 19, 2021. Details for each is as follows: GlobeNewswire Inc

Apr 28, 2021

04:05PM EDT Ziopharm Oncology, Inc. (Ziopharm or the Company) (Nasdaq: ZIOP), announced today that Laurence J.N. Cooper, PhD, MD, Scientific Advisor to the Company, was the inaugural presenter at Aldevrons Virtual Breakthrough Speaker Series. GlobeNewswire Inc

Apr 19, 2021

08:05AM EDT Ziopharm Oncology Announces First Patient Infused In CD19 RPM CAR-T Phase I Clinical Trial Being Conducted By Joint Venture Partner Eden BioCell Benzinga

08:00AM EDT Ziopharm Oncology, Inc. (Ziopharm or the Company) (Nasdaq: ZIOP), announced today that in March, the first patient was infused in the CD19-Specific Rapid Personalized Manufacturing (RPM) CAR-T Phase I Trial, being conducted by Eden BioCell, its joint venture with TriArm Therapeutics. GlobeNewswire Inc

Apr 7, 2021

09:01AM EDT Ziopharm Oncology To Present Poster At American Association For Cancer Research Virtual 2021 Annual Meeting Benzinga

09:00AM EDT Ziopharm Oncology, Inc. (Ziopharm or the Company) (Nasdaq: ZIOP), announced today it will be presenting a poster at the upcoming American Association for Cancer Research (AACR) Virtual 2021 Annual Meeting. GlobeNewswire Inc

Mar 12, 2021

08:24AM EST 10 Biggest Price Target Changes For Friday Benzinga

07:12AM EST Jefferies Downgrades ZIOPHARM Oncology to Hold, Lowers Price Target to $5 Benzinga

Mar 1, 2021

10:14AM EST Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2021 Benzinga

06:45AM EST HC Wainwright & Co. Downgrades ZIOPHARM Oncology to Neutral Benzinga

Feb 25, 2021

05:06PM EST ZIOPHARM Oncology Q4 EPS $(0.11) Misses $(0.10) Estimate Benzinga

08:08AM EST The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants Benzinga

04:03AM EST Earnings Scheduled For February 25, 2021 Benzinga

Feb 16, 2021

04:01PM EST Ziopharm Oncology, Inc. (the Company) (Nasdaq: ZIOP), today announced the Company will host a conference call and webcast to discuss financial results for the fourth quarter and full year 2020 on Thursday, February 25, 2021 at 4:30pm EDT. GlobeNewswire Inc

Feb 9, 2021

08:10AM EST The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement Benzinga

Feb 5, 2021

09:05AM EST Ziopharm Oncology Adds Robert Postma To Its Board RTTNews

09:01AM EST Ziopharm Oncology, Inc. (Ziopharm or the Company) (Nasdaq:ZIOP) today announced the election of Robert Postma to its Board of Directors (the Board), effective immediately. Mr. Postma is the Founder of WaterMill Asset Management, a sizeable and long-term shareholder of Ziopharm. GlobeNewswire Inc

Jan 29, 2021

07:45AM EST The Daily Biotech Pulse: Novavax Vaccine Readout, Clinical Hold On Bellicum Study Lifted, Lilly Earnings, NLS Pharma IPO Benzinga

Jan 14, 2021

08:12AM EST Ziopharm Oncology Names James Huang As Chairman RTTNews

08:12AM EST Ziopharm Oncology Announces Election Of James Huang As Chairman Of Board Of Directors Benzinga

08:00AM EST Mr. Huang is a veteran industry entrepreneur with 20+ years founding and funding biotech innovation GlobeNewswire Inc

Jan 7, 2021

04:30PM EST Discovery Capital Management Reports In 13G Filing A 5.13% Stake In Ziopharm Oncoloy Benzinga

Dec 23, 2020

04:01PM EST Ziopharm Oncology, Inc. (Ziopharm or the Company) (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a fireside chat at the H.C. Wainwright Bioconnect 2021 Conference and will deliver a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference. GlobeNewswire Inc

Dec 22, 2020

07:45AM EST The Daily Biotech Pulse: Ziopharm To Start Blood Cancer Study, Chemocentryx & Soligenix Slump On Adverse Clinical Trial Outcomes Benzinga

Dec 21, 2020

04:03PM EST Ziopharm Oncology Announces Clearance Of Taiwan's First IND Of Non-viral CAR-T For Treatment Of Relapsed CD19+ Leukemias And Lymphomas Benzinga

04:01PM EST Advances Eden BioCells clinical program to validate Rapid Personalized Manufacturing (RPM) GlobeNewswire Inc

Dec 17, 2020

09:00AM EST WaterMill Asset Management Issues Statement Regarding Consent Solicitation at Ziopharm Oncology Business Wire

08:10AM EST The Daily Biotech Pulse: MacroGenics Breast Cancer Drug Wins FDA Approval, Adcom Test Awaits Moderna, Virios To Make Wall Street Debut Benzinga

Dec 16, 2020

04:02PM EST Ziopharm Offers Comment On Consent Solicitation Results Benzinga

04:01PM EST Ziopharm Comments on Consent Solicitation Results GlobeNewswire Inc

Dec 15, 2020

07:52AM EST The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding Benzinga

Dec 14, 2020

04:03PM EST Ziopharm Oncology Announces Satyavrat Shukla Will Step Down From Chief Financial Officer Benzinga

04:02PM EST Ziopharm Oncology, Inc. (Nasdaq: ZIOP) (Ziopharm or the Company), today announced that Satyavrat Sath Shukla, CFA, Chief Financial Officer, has informed the Company of his intention to step down from the role effective December 31, 2020 to pursue another opportunity. The Company has initiated a search for a new Chief Financial Officer. GlobeNewswire Inc

Dec 13, 2020

04:27PM EST WaterMill Asset Management Addressed Ziopharm Oncology's Latest Distortion and Recent Threat; Clarifies That Decision to Extend Consent Goal Date to December 15 Stems From a Proxy Advisory Firm Improperly Executing Shareholder Votes Benzinga

Dec 12, 2020

05:15PM EST WaterMill Asset Management Addresses Ziopharm Oncology's Latest Distortion and Recent Threat Business Wire

Dec 11, 2020

06:57PM EST Ziopharm Recommends Shareholders Return the GREEN Consent Revocation Card GlobeNewswire Inc

Dec 10, 2020

07:01PM EST Egan-Jones Recommends Against Electing GlobeNewswire Inc

Dec 8, 2020

09:00AM EST WaterMill Asset Management Reinforces the Need for Meaningful and Urgent Change at Ziopharm Oncology Business Wire

Dec 4, 2020

09:10AM EST Ziopharm Sends Letter To Shareholders Urging Them To Support Continued Progress, Long-term Prospects RTTNews

08:30AM EST Has Held Several Discussions with WaterMill to Reach an Amicable Resolution to Consent Solicitation GlobeNewswire Inc

Dec 2, 2020

09:00PM EST Glass Lewis Recommends Ziopharm Shareholders Vote on the WHITE Consent Card for All of WaterMill's Director Candidates and Proposals Business Wire

Nov 28, 2020

05:30PM EST WaterMill Asset Management Refutes Ziopharm Oncology's Desperate, Low-Road Smear Campaign Business Wire

Nov 27, 2020

05:32PM EST ISS Acknowledges Ziopharms Outperformance of its Peer Group During Chairman Scott Tarriffs Tenure GlobeNewswire Inc

Nov 25, 2020

08:30PM EST ISS Recommends Ziopharm Shareholders Vote for Change on WaterMill Asset Management's WHITE Consent Card Business Wire

Nov 24, 2020

09:00AM EST WaterMill Asset Management Sets the Record Straight Following Ziopharm's Apparent Attempt to Mislead Shareholders and Rewrite History Business Wire

Nov 20, 2020

11:00AM EST Ziopharm Releases Investor Presentation Highlighting Execution of GlobeNewswire Inc

Nov 19, 2020

09:30AM EST WaterMill Asset Management Releases Presentation Detailing the Case for Urgent Change Atop Ziopharm Oncology Business Wire

09:10AM EST Ziopharm Oncology Highlights Presentation Of Data For Controlled IL-12 At 2020 Society For Neuro-Oncology Annual Meeting Benzinga

09:02AM EST White Rock Capital Supports WaterMill's Case for Change at Ziopharm Oncology PR Newswire

09:00AM EST First Data from Ongoing Phase 2 Study of Controlled IL-12 in Combination with Cemiplimab Demonstrate Promising Safety Profile in rGBM,and a Confirmed Partial Response GlobeNewswire Inc

Nov 17, 2020

04:16PM EST Ziopharm Oncology Appoints Raffaele Baffa, M.D., Ph.D., as Chief Medical Officer Benzinga

04:15PM EST Pharmaceutical Executivewith 20+ Years of ExperienceAcross All Phases of Clinical Research Including IND Submissions, Trial Design andRegulatory Filings GlobeNewswire Inc

Nov 16, 2020

08:30AM EST Special Advisor and Former Chief of Staff for the Bill & Melinda Gates Medical Research Institute Joins as Independent Director GlobeNewswire Inc

Nov 13, 2020

09:15AM EST Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on November 19, 2020 at 1:45 pm ET. GlobeNewswire Inc

09:08AM EST Level One Partners Reports Will Vote 100% Of Its ~10.7M Shares Of Ziopharm In Support Of WaterMill Asset Mgmt. Proposal For Reconstituted Board Benzinga

Nov 12, 2020

09:00AM EST WaterMill Asset Management Releases Candid Q&As with Each of its Director Candidates for Election to Ziopharm Oncology's Board Business Wire

Nov 5, 2020

04:08PM EST ZIOPHARM Oncology Q3 EPS $(0.10) Misses $(0.09) Estimate Benzinga

09:08AM EST WaterMill Asks Ziopharm Oncology Shareholders To Consent To All Of Its Proposals RTTNews

09:06AM EST WaterMill Asset Management Sends Letter To Ziopharm Oncology Shareholders, Urges Shareholders To Vote For Firm's Independent Director Candidates Benzinga

09:05AM EST WaterMill Asset Management Sends Letter to Ziopharm Oncology Shareholders Business Wire

07:54AM EST The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping Benzinga

04:34AM EST Earnings Scheduled For November 5, 2020 Benzinga

Nov 2, 2020

09:11AM EST Ziopharm Files Definitive Consent Revocation Statement, Sends Letter To Shareholders; Urges Shareholders To Sign, Return Co's GREEN Consent Revocation Card Benzinga

09:00AM EST Urges Shareholders to Sign and Return Ziopharms GREEN Consent Revocation Card GlobeNewswire Inc

08:46AM EST WaterMill Asset Management Launches Consent Solicitation To Reconstitute Board Of Directors Of Ziopharm Oncology Benzinga

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 16, 2020

04:04PM EDT Ziopharm Oncology Announces Receipt Of Shareholders' Intent To Solicit Written Consents, Acknowledges Filing Of Consent Solicitation By WaterMill Asset Management Corp Benzinga

04:00PM EDT Ziopharm Oncology Announces Receipt of GlobeNewswire Inc

Oct 1, 2020

08:30AM EDT Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a fireside chat at the 7th Annual Jefferies Cell Therapy Virtual Summit on October 5, 2020 at 12:30 pm ET. GlobeNewswire Inc

Sep 22, 2020

08:42AM EDT Ziopharm Oncology Appoints Kevin Buchi To Board RTTNews

08:30AM EDT Life Sciences industry veteran; 15-year Cephalon executive, serving progressivelyas CFO, COO and then CEO at time of $6.8 billion acquisition by Teva GlobeNewswire Inc

Sep 15, 2020

08:45AM EDT Ziopharm Oncology Appoints Four Additional Members To Scientific Advisory Board RTTNews

08:30AM EDT Ziopharm Oncology, Inc. (Ziopharm or the Company) (Nasdaq: ZIOP), today announced the appointment of four additional members to its Scientific Advisory Board (SAB). The SAB, under the leadership of Carl June, M.D. as chairman, will provide strategic and scientific counsel to guide development of Ziopharms pipeline of immunotherapies to treat patients with solid tumors. GlobeNewswire Inc

Sep 14, 2020

08:35AM EDT Ziopharm: FDA Grants Rare Pediatric Disease Designation For Controlled IL-12 For Diffuse Intrinsic Pontine Glioma RTTNews

08:33AM EDT Ziopharm Oncology Granted Rare Pediatric Disease Designation For Controlled IL-12 For Treatment Of DIPG Benzinga

08:30AM EDT Ziopharm Oncology Granted Rare Pediatric Disease Designation for GlobeNewswire Inc

Sep 10, 2020

09:00AM EDT Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in two upcoming conferences: GlobeNewswire Inc

Aug 6, 2020

04:43PM EDT ZIOPHARM Oncology Q2 EPS $(0.09), Inline Benzinga

07:57AM EDT The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO Benzinga

Jul 28, 2020

09:00AM EDT Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced the Company will host a conference call and webcast on Thursday, August 6, at 4:30 pm EDT to provide a corporate update and discuss financial results for the second quarter ended June 30, 2020. GlobeNewswire Inc

Jul 22, 2020

08:30AM EDT Industry veteran entrepreneur with 20+ years experience founding and financing successful, innovative biotech companies including GenScript and Legend Biotech GlobeNewswire Inc

Share